Human cytomegalovirus (HCMV) infection is highly speciesspecific, which means that it is unable to productively infect Table 1) .
Transplacental transmission and neonatal infections
The placentae of the guinea-pig and the rhesus macaque are structurally similar to the human placenta 1 . Experimental infections with RhCMV and GPCMV result in foetal infection, with clinical manifestations that include CNS involvement and (for GPCMV) sensorineural hearing loss (SNHL) 2, 6, 7 . Systemic maternal infection causes syndromes deleterious for the developing foetus, (e.g.
intrauterine growth restriction) with the incidence of foetal morbidity and mortality being highest when transmission occurs during early gestation 2, 3 . These key pathological features are similar to congenital HCMV infection 15 .
Despite poor transplacental transmission of MCMV in the laboratory setting, direct injection into the foetus or the newborn pup has been shown to mimic HCMV-induced congenital disease 12, 13 . Similar to RhCMV, the susceptibility of neuronal stem cells to MCMV infection is maturation stage-dependent, with a rapid resistance to infection of the brain developing after birth 16 . MCMV also infects the auditory nerve spiral ganglion and cochlea of newborn pups with measurable cytopathic effects and neuronal loss, and thus offers an amenable model for studying viral and host factors that contribute to SNHL 17 . 
Evaluation of antiviral therapies to ameliorate effects of congenital infection

Vaccination studies
Because maternal immunity reduces the severity of congenital CMV disease, the development of a vaccine is a high priority 22 . The GPCMV model has been used extensively for evaluating vaccine efficacy, by virtue of the ability to quantify the maternal immune responses, virus loads, as well as developmental sequelae 10 . Several GPCMV vaccines (live attenuated, subunit and DNA) administered before conception, have been evaluated 5, 11 . Whilst sterilising immunity to any vaccination program has not been demonstrated, 5, 6, 11, 23 . The use of vectored approaches for the delivery of subunit GPCMV vaccines that provide both cellular and humoral immunity also significantly reduce the incidence of congenital GPCMV infection 5, 24 . Notably, transplacental transmission of GPCMV has been observed in dams that had been previously infected, a feature in common with the evidence of symptomatic HCMV congenital infections resulting from maternal re-infections during pregnancy 25 .
To date, there have been few RhCMV vaccination studies, confined to immunogenicity, rather than efficacy studies. This is due in part by the paucity of seronegative colonies. Nevertheless, the RhCMV model has been useful to identify optimal vaccination regimes and immunogens that elicit strong cellular and humoral immune responses, using heterologous DNA prime-protein boost 
Other animal models
The potentials of rat CMV (RCMV) or porcine CMV (PCMV) as models of HCMV congenital infection have not been explored.
PCMV is of interest because natural maternal infection results in
transplacental transmission and thus it may provide an authentic evaluation of vaccination efficacy 29 . There has been a recent report of placental infection of rats with a novel RCMV 30 . If further studies demonstrate foetal infection, then this model would provide a highly amenable approach to testing intervention strategies.
Future Perspectives
Several advances are facilitating refinement of the above animal models for congenital HCMV: 
